AMIR REHMAN: Open Payments
NPI 1801983176 · ALEXANDRIA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$551 in 24 payments from 9 companies in 2025. Trend: 2023 $2,037 · 2024 $957 · 2025 $551
Food & beverage: $551
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 7 | $139 |
| ABBVIE INC. | 5 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Axsome Therapeutics, Inc. | 2 | $64 |
| Alkermes, Inc. | 2 | $52 |
| Bard Peripheral Vascular, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $33 |
| Lundbeck LLC | 1 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
Products named: Qelbree, REXULTI, VRAYLAR, Sunosi, ARISTADA, Venovo, CAMZYOS, INVEGA SUSTENNA.
Industry payments across VA — which companies pay providers there.
